Novo Nordisk, Merck and GSK announced they will refund covered entities following certain overcharges for 340B drugs.

Novo Nordisk, Merck, GSK to Refund 340B Covered Entities for Overcharges

May 30, 2025 Bella Czajkowski, National Correspondent Views

Three drugmakers will refund covered entities that purchased certain 340B-priced medications following recent adjustments to their 340B drug ceiling prices. [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Novo Nordisk, Merck, GSK to Refund 340B Covered Entities for Overcharges

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Bella Czajkowski

Novo Nordisk, Merck, GSK to Refund 340B Covered Entities for Overcharges

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Bella Czajkowski

Staff Email

Site Footer Live